Latest news with #Charney
New York Post
01-06-2025
- Business
- New York Post
$1B residential project kicks off in Gowanus — as ‘starchitect' reveals vision for 1,000-unit rental tower
BIG is back – and better — in Gowanus. The developers of 175 Third St. tapped Bjarke Ingalls' much-in-demand architectural firm to design their planned, 1,000-unit, rental apartment tower – and it's nothing like BIG's earlier concept for previous site-owner Aby Rosen's RFR Realty. The new 175 Third St. from Charney Companies and Tavros will stand 27 stories encompassing over 1 million square feet – the fifth building by the partners on four different sites on the Gowanus Canal's eastern side. 4 A rendering of 175 Third St. in Gowanas, Brooklyn. Bucharest Studio The images on this page reveal Ingalls' new vision for the first time, which the architect described as 'stacked blocks of cascading concrete volumes, cascading down toward the canal waterfront.' 'We had our eyes on the site forever,' Charney Companies principal Sam Charney said. 'But someone else always owned it' until 'the price finally came down [to $164 million] and we knew this was the time.' The purchase closed in May. When RFR bailed, it was expected that Charney and Tavros would choose a different architect. Instead, they liked Ingalls' new concept the best of the proposals they solicited from a half-dozen 'starchitects.' 4 175 Third St. rendering. Bucharest Studio 'We did not like the previous iteration,' Charney told Realty Check. 'It was inefficient and hard to build. It had a red-brick design that kind of drowned out the [red brick] Powerhouse Arts structure next door.' But Ingalls' new conception 'blew us away,' Charney said. Its textured 'architectural concrete' will look as if it's chiseled out of rock' — an homage to the area's industrial past. Chamfered, angled corners at various heights generate 'cool outdoor spaces.' A federal-supervised cleanup of the two-mile-long, noxious canal that began ten years ago prompted the city to rezone 82 blocks in the former low-rise manufacturing area for residential use. The rush to create nearly 9,000 new rental apartments spurred a construction boom. 4 Bucharest Studio A portion of the once-toxic canal – long a punch line of stand-up comedians – emerged as the district's unlikely scenic centerpiece. The waterway now suggests a picturesque, slow-moving river between handsome apartment towers on both sides. The waterfront promenade will eventually run the canal's length, with each developer responsible for the segment in front of their buildings. The ones Charney and Tavros are installing on their Nevins and Third Street frontages will be landscaped by Field Operations of High Line Park fame. Construction of 175 Third St. will likely start when the Nevins and Douglass Street buildings are finished roughly a year from now. 4 Rendering of the two buildings that will comprise Nevins Landing. Fogarty Finger The new 175 Third Street will have 1,000 rental units, of which 25% are 'affordable' as required by neighborhood Mandatory Inclusionary Zoning. It will follow Charney and Tavros' 224-unit Union Channel, which opened in February and is already 60% rented; and Douglass Port at 251 Douglass St. and Nevins Landing at 310 and 340 Nevins St., both under construction. Sam Charney estimated the development cost of 175 Third St., including the land purchase, at about $1 billion. With 100,000 square feet of retail space, it will be the crown jewel of what Charney and Tavros call a 'Gowanus Wharf campus' even though the buildings aren't next to each other. It will boast a 30,000 square-foot public park with 250 feet of canal boardwalk; sports facilities, a dog run, rooftop lounges, spa pools and a three-acre, landscaped courtyard, plus 35,000 square feet of lavish indoor amenities.
Yahoo
13-05-2025
- Health
- Yahoo
Mount Sinai Health System to Honor Dennis S. Charney, MD, Dean of the Icahn School of Medicine at Mount Sinai, for 18 Years of Leadership and Service at Annual Crystal Party
Will retire at the end of his current term on June 30; Eric J. Nestler, MD, PhD, appointed interim dean New York, NY, May 13, 2025 (GLOBE NEWSWIRE) -- Mount Sinai Health System announced today that it will recognize Dennis S. Charney, MD, the outgoing Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, for 18 years of leadership and service at its 40th annual Crystal Party, Tuesday, May 20, at Pier Sixty, 60 Chelsea Piers. Dr. Charney is one of the longest-serving deans of any medical school nationwide and will step down as Dean on Monday, June 30. He will remain on the faculty at the Icahn School of Medicine at Mount Sinai to continue his research and teaching. Dr. Charney, a preeminent expert in neurobiology who has made fundamental contributions to the understanding of human anxiety, fear, depression, and resilience, has played a key role in the discovery of new treatments for mood and anxiety disorders. He was recently named one of the 2025 TIME 100 Health Most Influential People in Health for his breakthrough treatments for depression. 'It has been my immense pleasure to lead this school and to be entrusted with shaping the vision and mission that has elevated Mount Sinai's standing in academic medicine,' said Dr. Charney. 'None of that would have been possible without the contributions of our faculty, staff, and students, all of whom have made serving the Icahn School of Medicine at Mount Sinai the greatest joy of my professional life. I look forward to seeing how the School will build on what we have created together.' Under Dr. Charney's leadership, the Icahn School of Medicine at Mount Sinai has advanced its reputation as an international leader in biomedical, scientific, and public health education, research, and clinical care. He recruited brilliant faculty members across the biomedical sciences, computational biology, and information technology, fostering a culture of innovation and scientific risk-taking. He also established more than two dozen interdisciplinary research institutions, fueling collaborations and investigations that have resulted in life-changing breakthroughs in the diagnosis and treatment of cancer, heart disease, gastrointestinal disease, and psychiatric illness. In addition to these achievements, Dr. Charney achieved dramatic growth in funding from the National Institutes of Health, which reached half a billion dollars in annual support in 2024, placing the Icahn School of Medicine at Mount Sinai No. 11 among medical schools and in the 99th percentile among U.S. private medical schools for research funding per principal investigator. He built the Icahn School of Medicine at Mount Sinai into the largest graduate medical program in the country, with more than 2,600 residents and clinical fellows. He also established partnerships with the Hasso Plattner Institute, Rensselaer Polytechnic Institute, and the State University of New York at Stony Brook to develop digital health products that are advancing precision medicine for the benefit of patients around the world. Dr. Charney was elected to the National Academy of Medicine in 2000 and has been honored with every major award in his field for his scientific research. He received the Colvin Prize for Outstanding Achievement in Mood Disorder Research in 2019 and the Rhoda & Bernard Sarnat International Prize in Mental Health from the National Academy of Medicine in 2023. He is a co-inventor of Ketamine, a rapidly acting US Food and Drug Administration (FDA)-approved antidepressant marketed as SPRAVATO™, has been hailed as one of the most exciting developments in antidepressant therapy in more than half a century. He is also the co-inventor of the first prescription digital therapeutic, marketed as Rejoyn, and approved by FDA for the treatment of major depressive disorder (MDD). 'Dennis Charney's legacy as one of the greatest transformational leaders in the history of academic medicine is well established and impressive. Through his efforts, he has put in place the people and resources that will ensure that the Icahn School of Medicine continues to excel in our mission to educate and train the physicians and scientists who will develop cutting-edge medical approaches to the greatest health challenges we face. We are grateful for all he has done for the School and the Health System,' said Brendan G. Carr, MD, MA, MS, Chief Executive Officer and Kenneth L. Davis, MD, Distinguished Chair of the Mount Sinai Health System. 'I always knew Dennis Charney would be a transformative leader,' said Kenneth L. Davis, MD, Executive Vice Chairman, Boards of Trustees, and former President and CEO, Mount Sinai Health System. 'His outside-the-box thinking, not restricted by tradition or a traditional leadership philosophy, and his thoughtfulness and strength would make him a steady leader to guide the School to greatness. He created a unique place of learning, teaching, and research, and I have been proud to be his partner and friend on this journey.' 'Dennis Charney is a visionary leader who has transformed the Icahn School of Medicine by creating an entrepreneurial capability inside our school where clinical and basic science research innovation thrive,' said Richard A. Friedman and James S. Tisch, Co-Chairs of the Mount Sinai Health System Boards of Trustees. 'He will be remembered as a pioneer who found a new bold and successful strategy for our school.' Eric J. Nestler, MD, PhD, has been appointed Interim Dean of the Icahn School of Medicine at Mount Sinai. One of the world's leading experts on the molecular mechanisms of drug addiction and depression, Dr. Nestler has been Dean for Academic Affairs of the Icahn School of Medicine and Chief Scientific Officer of the Mount Sinai Health System since 2016. He has authored more than 750 publications and five books, and his work has been recognized with the Wilbur Cross Distinguished Alumnus Medal from Yale University and the Peter Seeburg Prize in Integrative Neuroscience from the Society for Neuroscience. He has been a member of the National Academy of Medicine since 1998 and was recently elected to the National Academy of Sciences, one of the highest honors that a scientist can achieve, recognizing individuals for their distinguished and continuing achievements in original research. About the Mount Sinai Health System Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients' medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek's® 'The World's Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals' and by U.S. News & World Report's® 'Best Hospitals' and 'Best Children's Hospitals.' The Mount Sinai Hospital is on the U.S. News & World Report® 'Best Hospitals' Honor Roll for 2024-2025. For more information, visit or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube. CONTACT: Mount Sinai Press Office Mount Sinai Press Office newsmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
13-05-2025
- Entertainment
- Time of India
Trainwreck: The Cult of American Apparel OTT Release Date - When & where to watch docu on 2000s fashion scene
Trainwreck: The Cult of American Apparel OTT Release Date - Hold on to your seats, fashion watchers and true-story junkies, one of the most shocking stories in American fashion history is getting the Netflix treatment. Trainwreck: The Cult of American Apparel, a thrilling new documentary directed by Sally Rose Griffiths, is set to drop on Netflix on July 1, 2025, and it's going to make you look at your old American Apparel hoodie very differently. A bright brand hiding a dark truth Back in the early 2000s, American Apparel was everywhere with bold ads, bright basics, and that air of cool rebellion. It was a movement. Young people wanted to work there, shop there, be there. And at the centre of it all? Dov Charney, the brand's loud, charismatic, and often controversial founder. But what looked like a dream turned into a nightmare. This documentary pulls back the curtain on what really happened behind the scenes from the colourful chaos of the office floors to the dark allegations that would eventually bring it all crashing down. Charney's empire, built on sweatshop-free pride and edgy marketing, started to rot from within. Toxic culture or cult? Trainwreck: The Cult of American Apparel is a human story of young employees swept up in a whirlwind, thinking they were part of something big, only to realise they were part of something dangerous. The film gives voice to former staffers who once believed in the mission but found themselves caught in a toxic environment, with their professional dreams slowly unravelling. Produced by RAW and BBH, Trainwreck: The Cult of American Apparel's executive producers team includes Sheun Adelasoye De Nicola, Alexander Marengo, Tim Wardle (Raw); Casey Feldman, Erica Roberts, William Swann (BBH). Charney, who denies all allegations, has never been found guilty of any crimes, with lawsuits against him either settled or resolved behind closed doors.
Time Magazine
08-05-2025
- Health
- Time Magazine
Dennis Charney
When Dr. Dennis Charney, now dean of the Icahn School of Medicine at Mount Sinai, began researching the phenomenon of resilience, he could not have predicted the work would end up generating a breakthrough treatment for depression. Charney studied prisoners of war to better understand how the human mind copes with mental and physical trauma and found a common theme key to their survival: the prisoners described focusing on a mental task to distract themselves from their difficult reality. Some built a dream house in their head, while others mentally penned their future memoir. Still others practiced multiplying 12 numbers at a time. It took nearly 20 years of further research for Charney and his mentee at the time, Brian Iacoviello, to turn that observation into the first digital treatment for major depressive disorder, called Rejoyn. Further developed by the pharmaceutical company Otsuka, the app was cleared by the U.S. Food and Drug Administration (FDA) in 2024. People with depression practice a series of exercises that rebalance the cognitive and emotional functions of the brain—which, in depression, tend to skew toward negative emotional states like rumination. Users do the memory- and emotion-based exercises three to six times a week for six weeks, practicing their recall of faces expressing various emotional states. Interpreting human emotions while flexing memory muscles helps redirect the brain away from the circuits typical of depression. Brain imaging studies of people who used Rejoyn confirmed that their brains had changed, to more closely resemble the brains of people without depression. 'We showed, to my surprise, that their depression got better,' Charney says. Researchers are now studying whether the app can help those with other conditions such as PTSD.
Yahoo
04-05-2025
- Yahoo
Amphibians on the march for their Big Night
May 3—On warm, rainy spring nights, hundreds of volunteers stake out roads across Maine keeping watch for any movement. Their goal is to do what they can to usher some of the state's smallest creatures across to the road to ensure the next generation of amphibians will live to take the same trip in years to come. Maine's annual spring migration brings throngs of frogs and salamanders down from the forested uplands to shallow seasonal or vernal pools, where amphibians gather to breed each night. But the migration paths often take them across the state's network of paved roads, putting the frogs and salamanders at risk of death from traffic. Greg LeClair, biologist at Maine Department of Inland Fisheries and Wildlife, sought a solution to the carnage. In 2018 he founded Maine Big Night, a community science project that invites volunteers across Maine to help amphibians safely cross dark roads while collecting data to support long-term species survival. Derek Yorks, wildlife biologist at Inland Fisheries and Wildlife, said it's special to see synchronized migration between the various species. The most common migrating species in Maine are spotted salamanders, red-backed salamanders, blue spotted salamanders, four-toed salamanders, wood frogs and spring peepers, who can be heard nightly. On April 20, a law was passed to designate the spring peeper as Maine's official state amphibian. "They're all a little different, but their habitat is shared and the migration is shared," Yorks said. "So it can be quite the spectacle, definitely worth seeing for yourself if you get a chance." Opportunities to see amphibians aren't exclusive to nighttime. On a recent Saturday, the Sebasticook Regional Land Trust and Maine Master Naturalists held a vernal pool walk at Freedom Forest Reserve in Freedom, and the Kennebec Valley Land Trust hosted a vernal pool field workshop at the Ezra Smith Wildlife Conservation Area in Mount Vernon. They were just two of several vernal pool exploration events scheduled in April. These events increase human understanding of amphibians, said Noah Charney, assistant professor of conservation biology at the University of Maine who helped found the Maine Big Night nonprofit organization. "The understanding that people walk away with of what species are out there and what they need to survive, and understanding vernal pools and amphibians, I think, adds a layer of broader societal understanding and acceptance," Charney said, "and knowledge about what is in our world and what we need to do to protect it." While migration occurs over multiple nights, the Big Night is the night where conditions are optimal: rainy weather, wet roads and a temperature in the upper 40s or 50s. On those nights, amphibians race to be first to the pond so their larva can develop and metamorphosize before the pond dries up, Charney said. "They're trying to get there as soon as they thaw out, as soon as it's warm enough and wet enough for them to get there, and be the first to lay the eggs," Charney said, which are then fertilized. "So it's a race for these vernal pools in the early spring — the first warm, rainy night — although there's often a trickle of salamanders and frogs moving on a variety of different nights. But in general, the first warm, rainy night, they all try to get down to the ponds." This year, rainy nights throughout April brought earlier movement in southern Maine and a large peak night in central and northern Maine on April 15. Volunteers shared updates on species movement on Maine Big Night's Facebook page, noting location and weather conditions. The social media group is also home to hundreds of photos and videos of brightly colored frogs and salamanders, often perched in the hands of volunteers outfitted with headlamps and clad in reflective safety vests. Maine's amphibian species live the majority of their lives underground anywhere from a couple hundred to 1,000 feet from vernal pools. They venture out only to breed, making spring the perfect time to spot reclusive species before they return home. Charney said some amphibians stay in their hiding places for years. "If it's deep into late April, May, and there hasn't been any warm, rainy nights, at some point they're going to try to take whatever they can take to get down to those ponds," Charney said. "Or they'll decide to just skip the year entirely and wait until next year to migrate. Spotted salamanders in particular will do that." Synchronized amphibian migration happens across the Northeast each spring, but Maine Big Night was the first statewide, volunteer-led community science event, according to its website. Data has been recorded on over 20,000 amphibians since 2018. Charney said large-scale community science projects like Big Night reveal the pros and cons of human interaction with wildlife. Most times, he said, the positives win out. "There can definitely be a negative, direct impact felt by amphibians sometimes when there's too much interest in them," Charney said. "But I think that overall, in the bigger picture, I'd rather have more people excited about the amphibians and learning about them and understanding them and the kids playing with them — I think that in the long run, it has more positive impacts than the direct use of that wetland that night." Copy the Story Link
